Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Net Income (2017 - 2025)

Historic Net Income for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$39.3 million.

  • Protagonist Therapeutics' Net Income fell 1845.53% to -$39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 7314.91%. This contributed to the annual value of $275.2 million for FY2024, which is 44853.78% up from last year.
  • As of Q3 2025, Protagonist Therapeutics' Net Income stood at -$39.3 million, which was down 1845.53% from -$34.8 million recorded in Q2 2025.
  • Protagonist Therapeutics' Net Income's 5-year high stood at $207.3 million during Q1 2024, with a 5-year trough of -$41.0 million in Q2 2022.
  • Moreover, its 5-year median value for Net Income was -$33.2 million (2024), whereas its average is -$7.5 million.
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 33545.02% in 2021, then skyrocketed by 71479.61% in 2024.
  • Protagonist Therapeutics' Net Income (Quarter) stood at -$37.2 million in 2021, then increased by 7.77% to -$34.3 million in 2022, then skyrocketed by 179.78% to $27.3 million in 2023, then surged by 381.7% to $131.7 million in 2024, then crashed by 129.88% to -$39.3 million in 2025.
  • Its last three reported values are -$39.3 million in Q3 2025, -$34.8 million for Q2 2025, and -$11.7 million during Q1 2025.